What Changed in EU GMP Annex 1 for Visual Inspection?
The revised EU GMP Annex 1, "Manufacture of Sterile Medicinal Products," published in August 2022 and effective from August 25, 2023, represents the most significant overhaul of European sterile manufacturing regulations in over a decade. For visual inspection professionals, the changes are substantial — introducing new requirements for contamination control strategy integration, automated inspection validation, and inspector qualification that go well beyond the previous version.
This article breaks down the key changes that directly impact your visual inspection program, explains what regulators now expect, and provides practical guidance for achieving compliance.
The Previous Requirements (Pre-2022)
The old Annex 1, paragraph 124, was relatively brief on visual inspection:
"Filled containers of parenteral products should be inspected individually for extraneous contamination or other defects. When inspection is done visually, it should be done under suitable and controlled conditions of illumination and background. Operators doing the inspection should pass regular eye-sight checks, with spectacles if worn, and be allowed frequent breaks from inspection. Where other methods of inspection are used, the process should be validated, and the performance of the equipment checked at intervals. Results should be recorded."
While this established the principle of 100% inspection, it left significant room for interpretation regarding validation depth, challenge testing frequency, and integration with broader quality systems.
Key Changes in the 2022 Revision
1. Integration into Contamination Control Strategy (CCS)
The revised Annex 1 introduces the Contamination Control Strategy as a central organizing principle. Visual inspection is no longer treated as an isolated downstream activity — it must be explicitly integrated into your site's CCS. This means documenting how visual inspection contributes to your overall contamination control approach, including:
- How inspection detects failures in upstream controls (filling, sealing, environmental monitoring)
- How inspection data feeds back into process improvement
- How reject rates are trended and investigated as indicators of process health
2. Automated Inspection Validation (Section 8.32)
The most discussed change appears in paragraph 8.32:
"Where automated methods of inspection are used, the process should be validated to detect known defects (which may impact product quality or safety) and be equal to, or better than, manual inspection methods. The performance of the equipment should be challenged using representative defects prior to start up and at regular intervals throughout the batch."
This introduces two critical requirements:
- Equivalence or superiority to manual inspection: Your AVI system must demonstrably perform at least as well as qualified manual inspectors for all relevant defect types.
- Challenge testing throughout the batch: The equipment must be challenged not only at startup but at "regular intervals throughout the batch" — a requirement that has generated significant industry discussion.
3. The "Regular Intervals" Debate
The phrase "regular intervals throughout the batch" has been the subject of extensive industry interpretation. A March 2024 article in the PDA Letter by experts from Takeda, Sanofi, CSL Behring, and Merck (the BioPhorum visual inspection team) highlighted the risks of interpreting this literally:
- Stopping batch production to run challenge sets introduces mix-up risks between challenge units and real product
- Modern AVI systems continuously self-monitor critical parameters (camera position, light intensity, gate function) and alarm on drift
- The industry consensus favors event-driven challenges (after maintenance, failures, or prolonged downtime) rather than arbitrary time-based intervals
The recommended approach: perform challenge tests at batch start, and define in your procedures which specific events trigger mid-batch challenges. Document your rationale based on batch sizes, manufacturing frequencies, and risk assessment.
4. Container Closure Integrity (Sections 8.21–8.25)
The revised Annex 1 strengthens container closure integrity requirements:
- Final containers should be closed by appropriately validated methods
- Containers closed by fusion (ampoules, BFS) require 100% integrity testing
- Container closure integrity must be verified using validated, deterministic methods where feasible
- Visual inspection alone may not be sufficient for CCI verification — complementary methods may be required
5. Risk-Based Approach to Inspection Program Design
The revised Annex 1 mandates a risk-based approach throughout. For visual inspection, this means:
- Formal risk assessments to identify which defects are critical, major, or minor
- Inspection sensitivity calibrated to defect criticality
- Documentation of why certain inspection parameters were chosen
- Regular review and update of risk assessments based on new data
Practical Compliance Steps
For Manual Visual Inspection Programs:
- Update your CCS to explicitly include visual inspection as a contamination control element
- Review inspector qualification procedures — ensure they use characterized defect sets with known sizes and types
- Implement trending of reject rates by defect type, line, shift, and inspector
- Document your inspection conditions — light intensity (2,000–3,750 lux per USP <790>), backgrounds, viewing distance, and inspection time
- Establish requalification triggers — extended absence, vision changes, performance drift
For Automated Visual Inspection (AVI) Programs:
- Validate equivalence or superiority to manual inspection using Knapp-type studies with characterized defect sets
- Define your challenge testing strategy — document when and why challenges are performed, including event-driven triggers
- Implement continuous monitoring — leverage your AVI system's built-in parameter monitoring to demonstrate ongoing performance assurance
- Document your rationale for challenge frequency in a risk assessment that considers batch size, product type, and system capabilities
- Maintain recipe validation records — each product/container combination should have validated inspection parameters
How This Aligns with Other Regulations
The revised Annex 1 generally aligns with other major guidance documents:
- USP <790> and <1790>: The 100% inspection requirement and lifecycle approach are consistent
- FDA Draft Guidance (2021): Both emphasize risk-based approaches and integration with broader quality systems
- PDA Technical Report No. 44 (Revised 2023): Provides detailed implementation guidance that supports Annex 1 compliance
The key difference is Annex 1's explicit requirement for CCS integration and the "regular intervals" challenge testing language, which goes beyond what FDA or USP currently require.
Timeline and Enforcement
The revised Annex 1 became effective on August 25, 2023. EU/EEA manufacturers should already be in compliance. For companies exporting to the EU market, inspections by EU authorities will assess compliance against the revised requirements. Companies should be prepared to demonstrate:
- An updated CCS that includes visual inspection
- Validated AVI systems with documented challenge testing strategies
- Qualified manual inspectors with characterized defect sets
- Trending data showing continuous monitoring and improvement
How YB Inspection Can Help
Achieving compliance with the revised Annex 1 visual inspection requirements requires precision-manufactured defect test kits, validated surrogate solutions, and expert consulting support. YB Inspection provides:
- Particulate Defect Test Kits: Characterized defect sets for inspector qualification, Knapp studies, and AVI challenge testing — manufactured to documented specifications with certificates of analysis
- Surrogate Solutions: Custom formulations matched to your product's optical properties for controlled-substance or high-value drug inspection validation
- AVI/SAVI Support: Recipe development, validation protocol design, and challenge testing strategy consulting
- Compliance Consulting: Gap assessments against the revised Annex 1 requirements with practical remediation plans
Need help assessing your visual inspection program against the revised EU GMP Annex 1? Contact us for a consultation, or try Aydın, our AI-powered guidance tool that can answer your specific regulatory questions with cited sources.
